TTD | Drug: D05NIR

Drug General Information
Drug ID	D05NIR
Former ID	DIB003804
Drug Name	ALX-0061
Synonyms	Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx
Drug Type	Antibody
Indication	Autoimmune diabetes [ICD10:E08-E13]		Phase 2	[524991], [543089]
Company	Ablynx NV
Target and Pathway
Target(s)	Interleukin-6 receptor	Target Info		[533248]
KEGG Pathway	Cytokine-cytokine receptor interaction
	HIF-1 signaling pathway
	PI3K-Akt signaling pathway
	Jak-STAT signaling pathway
	Hematopoietic cell lineage
	Non-alcoholic fatty liver disease (NAFLD)
Reactome	MAPK3 (ERK1) activation
Reactome	MAPK1 (ERK2) activation
WikiPathways	SIDS Susceptibility Pathways
	Senescence and Autophagy in Cancer
	IL-6 signaling pathway
	Differentiation Pathway
	Interleukin-6 signaling
References
Ref 524991	ClinicalTrials.gov (NCT02287922) A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
Ref 543089	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363).
Ref 533248	The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information